Table 2: Characteristics of studies evaluating the role of FGS with 5-ALA on extents of resection ± post-operative survival in HGGs.

Study

Population

Intervention

Control

% of patients who received CRET

Mean EoR (%)

Median survival since intervention (months)

Significant survival benefit vs. control (months)

Intervention

Control

Intervention

Control

OS

PFS

OS

PFS

Della Puppa, et al. [22]

 

HGGs in eloquent areas only

FGS with functional mapping and iMRI (N = 31)

-

74

-

98.9

-

-

-

-

 

-

Schatlo, et al. [23]

HGGs

FGS and iMRI (N = 55)

No iMRI (N = 145)

45

30

-

-

17.9

10.6

None

None

Sharma, et al. [24]

HGGs

FGS and iMRI (N = 37)

-

97.3

-

99.9

-

31.2

-

-

-

Quick-Weller, et al. [25]

Recurrent HGGs only

FGS and iMRI (N = 7)

-

100

-

100

-

7.6

-

-

-

Archavlis, et al. [26]

Recurrent HGGs only

FGS, brachytherapy and temozolamide chemotherapy (N = 17)

Temozolamide chemotherapy only (N = 17)

59

-

-

-

8

7

3

3.5

Coburger, et al. [27]

HGGs

FGS and iMRI (N = 33)

iMRI only (N = 33)

75.8

-

99.7

97.4

18

6

None

None

Díez Valle, et al. [18]

HGGs

FGS and iMRI (N = 36)

-

83.3

-

99.8

-

11.8

-

-

-

Piquer, et al. [20]

HGGs

FGS and iMRI (N = 27)

-

79.3

-

-

-

-

-

-

-

HGG: High-Grade Gliomas (WHO grade  3); FGS: Fluorescence-Guided Surgery (with 5-ALA); Imri: Intra-Operative MRI; CRET: Complete Resection of Enhancing Tumour; EoR: Extent of Resection; OS: Overall Survival from treatment; PFS: Progression-Free Survival (time between surgery and development of new symptoms or progression of tumour on imaging)